Verrica Pharmaceuticals to Present Phase 2 Data on VP-315 at Major Immunotherapy Conference
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will present new data on its investigational oncolytic peptide therapy, VP-315, for the treatment of basal cell carcinoma …
Verrica Pharmaceuticals to Present Phase 2 Data on VP-315 at Major Immunotherapy Conference Read More